- Latest available (Revised)
- Point in Time (30/08/2017)
- Original (As made)
Version Superseded: 06/11/2023
Point in time view as at 30/08/2017.
There are currently no known outstanding effects for the The National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013,
PART 6
.
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
33.—[F1(A1) In this regulation, “A” means, where an application for inclusion in a pharmaceutical list is made by a person who is—
(a)an individual, the individual making the application;
(b)a partnership, any partner in the partnership making the application; or
(c)a body corporate—
(i)except for the purposes of paragraphs (1)(a) and (b) and (3)(h)(i), the body corporate making the application, and
(ii)except for the purposes of paragraph (2)(b) and (e), any director or superintendent of the body corporate making the application.]
(1) An application for inclusion in a pharmaceutical list by a person F2... who is not already included in it must be refused if the NHSCB is satisfied that—
(a)A F3...has been convicted in the United Kingdom of murder;
(b)A F3...—
(i)has been convicted in the United Kingdom of a criminal offence, other than murder, which was committed after 1st April 2005, and
(ii)has been sentenced to a term of imprisonment of over 6 months;
(c)A is the subject of a national disqualification; or
(d)where, on appeal, the First-tier Tribunal determines A may be included in the pharmaceutical list subject to conditions, A has not within 30 days of that decision notified the NHSCB that A agrees to the imposition of the conditions.
(2) An application for inclusion in a pharmaceutical list by a person who is not already included may be refused if the NHSCB—
(a)having contacted the referees mentioned in paragraph 3(8) of Schedule 2, is not satisfied with the references given;
(b)considers that A is unsuitable to be included in the list;
(c)having—
(i)checked with the NHS BSA for any facts that it considers relevant relating to past or current fraud investigations involving or related to A F4..., and
(ii)considered these and any other facts in its possession relating to fraud involving or relating to A F4...,
considers the outcome of these enquiries justify such refusal;
(d)having—
(i)checked with the Secretary of State for any facts considered by the Secretary of State to be relevant relating to past or current investigations or proceedings involving or relating to A F5..., and
(ii)considered these and any other facts in its possession involving or relating to A F5...,
considers the outcome of these enquiries justify such refusal; or
(e)considers that granting the application would be prejudicial to the efficiency of the service which A has undertaken to provide.
(3) Where the NHSCB is considering refusal of an application under paragraph (2), it must consider all facts which appear to it to be relevant and must in particular take into consideration in relation to paragraph (2)(b) to (e)—
(a)the nature of any offence, investigation or incident;
(b)the length of time since any offence, incident, conviction or investigation;
(c)whether there are other offences, incidents or investigations to be considered;
(d)any action taken or penalty imposed by any licensing or regulatory body, the police or the courts as a result of any such offence, incident or investigation;
(e)the relevance of any offence, investigation or incident to the provision by A of pharmaceutical services and any likely risk to users of pharmaceutical services or to public finances;
(f)whether any offence was a sexual offence to which Part 1 of the Sexual Offences Act 2003 M1 (sexual offences) [F6or section 2 of the Modern Slavery Act 2015 in respect of sexual exploitation (human trafficking)] applies, or if it had been committed in England and Wales, would have applied;
(g)whether A F7... has been refused inclusion in, conditionally included in, removed, contingently removed or is currently suspended from a relevant list for a reason relating to unsuitability, fraud or efficiency of service provision, and if so, the facts relating to the matter which led to such action and the reasons given by the NHSCB or another primary care organisation for such action; or
(h)whether A F7...was, at the time of the originating events, or has in the preceding 6 months been—
(i)a director or superintendent of a body corporate which has been refused inclusion in, conditionally included in, removed or contingently removed from a relevant list, or
(ii)is currently suspended from a relevant list,
for a reason relating to unsuitability, fraud or efficiency of service provision, and if so, what the facts were in each such case and the reasons given by the NHSCB or another primary care organisation in each case.
(4) When the NHSCB takes into consideration the matters set out in paragraph (3), it must consider the overall effect of all the matters being considered.
(5) If an application for inclusion in a pharmaceutical list by a person who is not already included in it is refused under paragraph (1) or (2), the NHSCB must notify the applicant of that decision and it must include with the notification an explanation of—
(a)the reasons for the decision;
(b)the applicant's right of appeal against the decision to the First-tier Tribunal, which must be exercised within 30 days of the date on which the applicant was notified of the decision.
Textual Amendments
F1Reg. 33(A1) inserted (1.4.2014) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 12(a)
F2Word in reg. 33(1) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 12(b)(i)
F3Words in reg. 33(1)(a)(b) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 12(b)(ii)
F4Words in reg. 33(2)(c)(i)(ii) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 12(c)
F5Words in reg. 33(2)(d)(i)(ii) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 12(c)
F6Words in reg. 33(3)(f) inserted (31.7.2015) by The Modern Slavery Act 2015 (Consequential Amendments) Regulations 2015 (S.I. 2015/1472), regs. 1, 12
F7Words in reg. 33(3)(g)(h) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 12(c)(d)
Marginal Citations
34.—[F8(A1) In this regulation, “A” means, where an application for inclusion in a pharmaceutical list is made by a person who is—
(a)an individual, the individual making the application;
(b)a partnership, any partner in the partnership making the application; or
(c)a body corporate—
(i)except for the purposes of paragraph (1)(b), (c)(ii), (e), (g), (i) and (k), the body corporate making the application, and
(ii)any director or superintendent of the body corporate making the application.]
(1) An application for inclusion in a pharmaceutical list by a person F9...who is not already included in it may be deferred if the NHSCB is satisfied that—
(a)there are, in respect of A F10...—
(i)criminal proceedings in the United Kingdom, or
(ii)proceedings elsewhere relating to conduct, which, if it had occurred in the United Kingdom, would constitute a criminal offence,
which, if they result in a conviction, or the equivalent of a conviction, would be likely to lead to [F11the person’s removal from the pharmaceutical list, if the person] were to be included in it;
(b)in respect of a body corporate of which A is, or has in the preceding 6 months been, or was at the time of the originating events, a director or superintendent, there are—
(i)criminal proceedings in the United Kingdom, or
(ii)proceedings elsewhere relating to conduct, which, if it had occurred in the United Kingdom, would constitute a criminal offence,
which, if they resulted in a conviction, or the equivalent of a conviction, would be likely to lead to [F12the person’s removal from the pharmaceutical list, if the person] were to be included in it;
(c)there is an investigation anywhere in the world—
(i)by A's F13... licensing or regulatory body, or
(ii)relating to A F14... in A's professional capacity (including one by the NHSCB or another primary care organisation),
which, if the outcome were adverse, would be likely to lead to the removal of [F15the person from the pharmaceutical list if the person] were to be included in it;
(d)A F16...is suspended from a relevant list;
(e)a body corporate of which A F17... was, at the time of the originating events, a director or superintendent, is suspended from a relevant list;
(f)the First-tier Tribunal is considering an appeal by A F18... against a decision of the NHSCB or another primary care organisation—
(i)to refuse an application for inclusion in a relevant list, or
(ii)to include A conditionally in, or to remove or contingently remove A from, a relevant list,
and if that appeal were to be unsuccessful, the NHSCB would be likely to remove [F19the person from the pharmaceutical list if the person] were to be included in it;
(g)the First-tier Tribunal is considering an appeal by a body corporate of which A F20... was, at the time of the originating events, or has in the preceding 6 months been, a director or superintendent, against a decision of the NHSCB or another primary care organisation—
(i)to refuse an application by that body corporate for inclusion in its list,
(ii)to include A conditionally in, or to remove or contingently remove A from, a relevant list,
and if that appeal were to be unsuccessful the NHSCB would be likely to remove [F21the person from the pharmaceutical list if the person] were to be included in it;
(h)A F22... is being investigated by the NHS BSA in relation to any fraud, where the result, if adverse, would be likely to lead to the removal of [F23the person from the pharmaceutical list if the person] were to be included in it;
(i)a body corporate, of which A F24...was, at the time of the originating events, a director or superintendent, is being investigated by the NHS BSA in relation to any fraud, where the result if adverse would be likely to lead to the removal of [F25the person from the pharmaceutical list if the person] were to be included in it;
(j)the First-tier Tribunal is considering an application from the NHSCB or a Local Health Board for a national disqualification of A F26...;
(k)the First-tier Tribunal is considering an application from the NHSCB or a Local Health Board for a national disqualification of a body corporate of which A F27... was, at the time of the originating events, a director or superintendent; or
(l)the NHSCB or another primary care organisation, for a reason relating to unsuitability, fraud or efficiency of service provision—
(i)is considering removal (other than voluntary removal) or contingent removal of the applicant from a relevant list, or
(ii)has taken a decision to remove (other than voluntary removal) or contingently remove [F28the applicant] from a relevant list but that decision has yet to take effect.
(2) The NHSCB may only defer a decision under paragraph (1) until—
(a)the outcome of the cause for the deferral is known; or
(b)the reason for the deferral no longer exists.
Textual Amendments
F8Reg. 34(A1) inserted (1.4.2014) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(a)
F9Word in reg. 34(1) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(i)
F10Words in reg. 34(1)(a) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(ii)(aa)
F11Words in reg. 34(1)(a) substituted (1.4.2014) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(ii)(bb)
F12Words in reg. 34(1)(b) substituted (1.4.2014) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(iii)
F13Words in reg. 34(1)(c)(i) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(iv)(aa)
F14Words in reg. 34(1)(c)(ii) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(iv)(bb)
F15Words in reg. 34(1)(c) substituted (1.4.2014) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(iv)(cc)
F16Words in reg. 34(1)(d) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(v)
F17Words in reg. 34(1)(e) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(vi)
F18Words in reg. 34(1)(f) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(vii)(aa)
F19Words in reg. 34(1)(f) substituted (1.4.2014) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(vii)(bb)
F20Words in reg. 34(1)(g) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(viii)(aa)
F21Words in reg. 34(1)(g) substituted (1.4.2014) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(viii)(bb)
F22Words in reg. 34(1)(h) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(ix)(aa)
F23Words in reg. 34(1)(h) substituted (1.4.2014) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(ix)(bb)
F24Words in reg. 34(1)(i) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(x)(aa)
F25Words in reg. 34(1)(i) substituted (1.4.2014) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(x)(bb)
F26Words in reg. 34(1)(j) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(v)
F27Words in reg. 34(1)(k) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(v)
F28Words in reg. 34(1)(l)(ii) substituted (1.4.2014) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(xi)
35.—(1) An application for inclusion in a pharmaceutical list by a person (P) who is not already included may be granted subject to a condition of a type mentioned in paragraph (3), which is determined by the NHSCB and which the NHSCB decides to impose with regard to P.
(2) The NHSCB may vary the terms of service of an NHS chemist for the purpose of or in connection with the imposition of the condition.
(3) A condition imposed under paragraph (1) must be a condition with a view to—
(a)preventing any prejudice to the efficiency of the services, or any of the services, which P has undertaken to provide; or
(b)preventing any act or omission within section 151(3)(a) of the 2006 Act (disqualification of practitioners).
(4) If the NHSCB decides to grant an application subject to a condition imposed under paragraph (1), it must notify P of that decision and it must include with the notification an explanation of—
(a)the reasons for the decision;
(b)P's right of appeal against its decision to the First-tier Tribunal;
(c)the time limit within which, in accordance with the Tribunal Procedure (First-tier Tribunal) (Health, Education and Social Care Chamber) Rules 2008 M2, the application notice must be sent to the Tribunal if an appeal is to be brought; and
(d)the effect of paragraph (5).
(5) If P issues a notice of commencement before the First-tier Tribunal has determined an appeal against a condition imposed under paragraph (1), P is to be included in the pharmaceutical list subject to the condition, but only pending the outcome of the appeal if the appeal is successful.
(6) The appeal is to be by way of redetermination of—
(a)the decision of the NHSCB to impose the condition; and
(b)if P has, at the time the appeal is determined, been included in the pharmaceutical list, any decision under paragraph (2) to vary the terms of service of P for the purpose of or in connection with the imposition of the condition.
(7) If at the time the appeal is determined, P has not been included in the pharmaceutical list, and—
(a)the First-tier Tribunal confirms the decision of the NHSCB; or
(b)imposes a different condition,
P must, within 30 days of P being notified of the First-tier Tribunal's decision, notify the NHSCB as to whether or not P wishes to withdraw P's application
(8) If P fails, in the circumstances described in paragraph (7), to notify the NHSCB within that 30 days that P does not wish to withdraw P's application, the grant of P's application lapses.
Marginal Citations
M2S.I. 2008/2699 (L 16); see rule 19 of those Rules.
The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Whole Instrument you have selected contains over 200 provisions and might take some time to download.
Would you like to continue?
The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: